Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2014-06-30 Declaration of Voting R…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement (1359 chars) titled 'Total Voting Rights Announcement' issued on 30 June 2014. It explicitly states the total number of voting rights (131,604,926) after the exercise of stock options. This content directly relates to changes in the total number of shares that carry voting rights. While it is a regulatory announcement, the specific nature of reporting total voting rights aligns most closely with announcements concerning capital structure or general regulatory updates. Since there is no specific code for 'Total Voting Rights Announcement', and it is not a declaration of *results* from a vote (DVA), nor a director's dealing (DIRS), nor a general share issue (SHA), it falls best under the general regulatory announcement category, RNS, as it is a mandatory disclosure under German law (WpHG Article 26a). Given its brevity and function as a mandatory disclosure, RNS is the most appropriate fallback.
2014-06-30 English
Evotec receives milestone payment as part of its discovery alliance with Boehringer Ingelheim
Regulatory Filings Classification · 99% confidence The document is a press release format, indicated by the 'News Details' header, date (19 June 2014), and the use of DGAP-News boilerplate language at the end, which often disseminates corporate news. The content announces a specific, non-financial event: receiving a milestone payment from a partner (Boehringer Ingelheim) as part of a discovery alliance. This is a general corporate update regarding business operations and partnership progress, not a mandatory regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate announcement disseminated via a news service (DGAP), and it doesn't fit into the more specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend (DIV), the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings). The document length (5828 chars) is substantial enough that it is the primary announcement itself, not just a notice of publication (RPA).
2014-06-19 English
Resolutions of the Annual General Meeting of Evotec AG
AGM Information Classification · 99% confidence The document is explicitly titled 'Resolutions of the Annual General Meeting of Evotec AG' and details the outcomes of the meeting, including the approval of management actions, the election of a new Supervisory Board, and the creation of Authorised Capital. This content directly relates to the proceedings and results of the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document is a summary/release of the AGM results, not just a voting result announcement (DVA) or a proxy solicitation (PSI).
2014-06-17 English
Präsentation zur Hauptversammlung 2014
AGM Information Classification · 98% confidence The document text is structured like a presentation, featuring an 'Agenda', sections titled 'Begrüßung und Vorstellung' (Welcome and Introduction), historical context ('20 Jahre Forschung'), strategic overviews ('EVT Execute und EVT Innovate'), detailed pipeline tables, and specific deep dives into therapeutic areas like Diabetes and Alzheimer's. The content is highly strategic, forward-looking, and includes detailed operational and financial partnership structures. This format and content strongly suggest an Investor Presentation (IP) or a presentation given at an Annual General Meeting (AGM-R). Since the document explicitly mentions 'Hauptversammlung 2014' (Annual General Meeting 2014) in the title and the content aligns perfectly with materials presented to shareholders regarding strategy, performance, and pipeline, AGM-R is the most precise classification, although IP is also very close. Given the explicit mention of the AGM date and context, AGM-R is selected.
2014-06-17 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a of the WpHG (German Securities Trading Act). It announces a change in the total number of voting rights due to the exercise of stock options. This type of announcement, which reports on the total number of shares with voting rights, is a specific regulatory disclosure. While it relates to capital structure, it is most closely aligned with official regulatory notifications regarding ownership/voting power changes, which often fall under general regulatory filings or specific voting-related categories. Given the options, it is a specific regulatory announcement about voting rights, but it is not the results of a vote (DVA) or a general capital change (SHA/POS). Since it is a mandatory regulatory disclosure about voting rights, and there isn't a perfect fit for 'Voting Rights Disclosure', it is best classified as a general Regulatory Filing (RNS) as it is a mandatory, non-financial report announcement distributed via a service like DGAP.
2014-05-30 English
Evotec to establish an anti-infectives platform with the acquisition of Euprotec Ltd
M&A Activity Classification · 99% confidence The document is a press release dated May 28, 2014, announcing the acquisition of Euprotec Ltd by Evotec AG. The key phrases are 'Mergers & Acquisitions' (Key word(s)), 'acquisition of all shares', and details about the purchase price and expected closing date. This clearly falls under the category of corporate activity related to M&A, which corresponds to the 'TAR' (M&A Activity) filing type.
2014-05-28 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.